Ardea Biosciences (RDEA -0.1%) says it's earned a $7.5M milestone payment from Bayer (BAYRY.PK) under the terms of their April 2009 global license agreement to develop and commercialize RDEA's mitogen-activated ERK kinase inhibitor compounds for cancer and other indications. The milestone was triggered by the recent initiation of Phase 2 clinical studies. Separately, Gabelli says it's raised its stake in the company from 7.9% to 8.94%.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs